Journal
ONCOTARGET
Volume 7, Issue 27, Pages 41172-41185Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9226
Keywords
glioblastoma; ganglioside; immunotherapy
Categories
Funding
- Agence Nationale pour la Recherche [ANR-13-RPIB-0001]
- Agence Nationale de la Recherche (ANR) [ANR-13-RPIB-0001] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available